PDS Biotechnology Corporation

NASDAQ:PDSB   3:59:52 PM EDT
3.77
-0.13 (-3.33%)
Products, Regulatory

Pds Biotech Announces Presentation Of Efficacy And Safety Data From Versatile-002 Phase 2 Clinical Trial In Recurrent Or Metastatic Head And Neck Cancer At Asco 2022

Published: 05/26/2022 23:57 GMT
PDS Biotechnology Corporation (PDSB) - Pds Biotech Announces Presentation of Efficacy and Safety Data From Versatile-002 Phase 2 Clinical Trial in Recurrent Or Metastatic Head and Neck Cancer at Asco 2022.
Pds Biotechnology - No Treatment-related Adverse Events Greater Than Or Equal to Grade 3 From Versatile-002 Phase 2 Trial.
Pds Biotechnology - No Patients Required Dose Interruption Or Reduction on Combination Treatment for Versatile-002 Clinical Trial.
Pds Biotechnology - 76.5% of Patients Had Either Disease Stabilization Or Tumor Shrinkage for Versatile-002 Clinical Trial.
Pds Biotechnology - 89% of Patients Alive at Median 9 Months Suggesting Survival Benefit in Versatile-002 Clinical Trial.
Pds Biotechnology - Versatile-002 Clinical Trial Combination Treatment Well Tolerated to Date.